Pre-Market Most Active for Dec 31, 2025 : TSLL, TQQQ, NVDA, VNDA, NIO, INTC, MSTX, NKE, XPEV, SMR, BBAI, ORC

The NASDAQ 100 pre-market indicator was up 10.97 to 25,473.53 with total pre-market volume of 46,748,616 shares. The most active pre-market names included Direxion Daily TSLA Bull 2X (TSLL) trading 2.76M shares at $19.68 (+212.88% from its 52-week low), ProShares UltraPro QQQ (TQQQ) 1.90M shares at $53.94 (noting a $0 cash dividend with an Ex/Eff date of 12/31/2025), and NVIDIA (NVDA) 1.84M shares at $188.77 (Zacks mean recommendation in the buy range). Other notable mentions: Vanda Pharmaceuticals (VNDA) and XPeng (XPEV) flagged as Zacks 'buy range', NIO and INTC trades noted relative to their target prices (NIO at 83.44% of $6.40 target; INTC at 98.03% of $38.50 target), Nike (NKE) reported three upward EPS revisions over the last four weeks with a consensus EPS of $0.74 for the fiscal quarter ending Nov 2026, and NuScale (SMR) trading at 44.56% of its $32 target.

Analysis

Market structure: Pre-market volume clustering in NVDA, leveraged ETF TSLL and TQQQ signals a risk-on microstructure where AI/semiconductor exposure is the marginal buyer; NVDA and semicap suppliers are near-term winners while legacy CPU companies (INTC) and small-cap cyclicals (SMR) face relative pressure. Retail flow into 2x/3x products (TSLL, TQQQ) increases intraday gamma and amplifies moves >3–5%, raising short-term volatility and liquidity costs for option sellers.

Risk assessment: Tail risks include US/China export controls on AI chips, a negative NVDA guide, or a sudden ETF deleveraging that could compress risk premia (move bond yields +10–25 bps in a risk-off shock). Time horizons split: days—elevated IV and squeeze risk; weeks—earnings/guidance and inventory data; quarters—chip demand cyclicality and secular AI adoption. Hidden dependencies: NVDA upside is levered to hyperscaler capex and Chinese demand; INTC downside is tied to foundry/Intel 4 cadence and margin recovery timing.

Trade implications: Direct plays: bias long NVDA and short cyclicals/legacy compute (INTC) as a pair; use size discipline (2–3% directional equity exposure, 1–2% on shorts) and options to define risk. For volatility, favor debit call spreads on NVDA (1–3 month) and buy protection (buy puts or collars) on leveraged ETF exposure; rotate modest capital from broad tech beta into AI-focused names and cash bonds if risk premium compresses.

Contrarian angles: Consensus underweights the fragility of leveraged ETF flows—rising retail participation can exacerbate drawdowns; NVDA’s near-term upside is priced for continued superbearnings (>10% move) so downside from a single soft guide is underappreciated. SMR’s negative sentiment may be overdone if nuclear SMR policy tailwinds reappear; ORC is crowded near target—buy for yield only with tight stops.

Key Decisions for Investors

• Establish a 2–3% long position in NVDA (ticker NVDA) using a defined-risk 1–3 month 190/220 call spread to target 12–25% upside while limiting max loss to the premium paid; place stop-loss if NVDA breaks below $170 on daily close.
• Initiate a pair trade: long NVDA (1.5% portfolio) vs short INTC (1.5%) for a 3-month horizon—short INTC with a stop-limit buy-to-cover at $40 and take-profit if INTC falls to $33, expecting relative outperformance driven by AI capex.
• Avoid outright long SMR until clarity on program funding; consider a small (≤0.5%) speculative put-sell or short if catalysts (government funding, licensing) do not materialize within 90 days—risk limit: max draw to 1% portfolio.
• Buy ORC for income capture with a 1–2% allocation targeting total return: buy at market ($7.23), set a tight stop at $6.50 and a sell target near $7.50–$8.00 within 3–6 months to capture yield and small capital upside.